Effect of probucol on elderly hypercholesterolemic patients in the FAST study.
The present study involved a detailed post hoc comparison of the efficacy and safety of lipid-lowering therapy in elderly hypercholesterolemic patients from the Fukuoka Atherosclerosis Trial (FAST). The FAST cohort of 246 hypercholesterolemic patients included 76 patients who were (75 years old. Patients were randomized to receive probucol (500 mg/day) or pravastatin (10 mg/day) therapy, or to a control group (diet alone), and then were followed for 2 years. In patients > or = 75 years old, either probucol or pravastatin achieved a significant reduction of carotid intima-media thickness (IMT). In patients <75 years old, lipid-lowering therapy also achieved a significant reduction of IMT. In patients > or = 75 years old receiving probucol, the relative risk (95% confidence interval) of all-cause mortality was 0.15 (0.02 to 1.28) and that for major coronary events was 0.12 (0.02 to 1.04). In conclusion, probucol reduced the incidence of cardiovascular disease in elderly hypercholesterolemic patients as well as younger patients.
Sawayama
Yasunori
Y
Department of General Medicine, Kyushu University Hospital, Fukuoka, Japan. sawayama@genmedpr.med.kyushu-u.ac.jp
Maeda
Shinji
S
Ohnishi
Hachirou
H
Okada
Kyoko
K
Hayashi
Jun
J
D000328:Adult; D000367:Age Factors; D000368:Aged; D000369:Aged, 80 and over; D000924:Anticholesteremic Agents / Q000627:therapeutic use*; D050197:Atherosclerosis / Q000209:etiology / Q000473:pathology; D002318:Cardiovascular Diseases / Q000209:etiology / Q000517:prevention & control; D002339:Carotid Arteries / Q000473:pathology; D002340:Carotid Artery Diseases / Q000209:etiology / Q000473:pathology; D015331:Cohort Studies; D005260:Female; D006801:Humans; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors / Q000627:therapeutic use; D006937:Hypercholesterolemia / Q000150:complications / Q000188:drug therapy*; D015994:Incidence; D008297:Male; D008875:Middle Aged; D017035:Pravastatin / Q000627:therapeutic use; D011341:Probucol / Q000627:therapeutic use*; D012306:Risk; D016896:Treatment Outcome
D000924:Anticholesteremic Agents; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors; D017035:Pravastatin; D011341:Probucol